Biotech Deals by the Numbers
Executive SummaryBig pharma-biotech dealmaking continues to increase in popularity and price--companies with later-stage products are finding they truly can drive better deals. Meanwhile, drug companies are increasingly paying for their dealmaking with equity, as they leverage their balance sheet to offset research expenses.
You may also be interested in...
Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.